GPCRTwo shots on goal
Structure Therapeutics is giving investors a little biotech dopamine hit. The company reported positive clinical data across two oral small-molecule programs aimed at chronic weight management: ACCG-2671, an amylin receptor agonist, and aleniglipron, a GLP-1 receptor agonist.
ACCG-2671 showed a roughly 6-day half-life, no serious adverse events, and signs the drug is doing what it’s supposed to do, including up to 3.3% body weight loss in the Phase 1/2a single ascending dose study. That’s early-stage stuff, but in biotech, early-stage stuff is often the whole mood.
The GLP-1 angle is doing the heavy lifting
Aleniglipron is the bigger headline. In the ACCESS OLE clinical trial, the drug showed up to 16.2% mean body-weight reduction at 72 weeks, with no observed plateau and better tolerability after a 2.5 mg starting dose. The company also said study-drug discontinuation rates due to adverse events stayed below 5%.
That matters because obesity drugs live and die on two things: how much weight they move and how miserable they make people feel while doing it. If you can keep efficacy high and the bathroom-stall drama low, the market tends to pay attention.
What’s next?
The pipeline doesn’t exactly sprint from here. Structure Therapeutics said it has started dosing the 12-week MAD portion of the ACCG-2671 Phase 1/2a trial, with topline data expected in 1H 2027. Meanwhile, the registrational Phase 3 trials for aleniglipron — ACCOMPLISH-1 and ACCOMPLISH-2 — are still enrolling, with topline data expected in 2H 2028.
So yes, the data looks encouraging. But biotech investors know the drill: today’s victory lap can turn into tomorrow’s “please wait while we enroll more patients.”
Big picture: this is a solid de-risking step for Structure Therapeutics, and the obesity market remains one of the hottest prize fights in pharma.